

November 13, 2023



Current Price: ₹ 5273.35

STOCK DATA

BSE Code	532488
NSE Symbol	DIVISLAB
Reuters	DIVI.BO
Bloomberg	DIVI IN

VALUE PARAMETERS

52 W H/L(Rs)	5362.00/4078.40
Mkt. Cap.(Rs Cr)	75822.68
Latest Equity(Subscribed)	71.89
Latest Reserve (cons.)	6428.90
Latest EPS (cons.) -Unit Curr.	48.42
Latest P/E Ratio -cons	108.91
Latest Bookvalue (cons.) -Unit Curr.	452.12
Latest P/BV - cons	11.66
Dividend Yield -%	0.28
Face Value	5

SHARE HOLDING PATTERN (%)

Description as on	% of Holding 30/09/2023
Foreign	46.92
Institutions	18.60
Govt Holding	0.23
Non Promoter Corp. Hold.	0.37
Promoters	29.33
Public & Others	4.57

Consolidated Financials Results

In Cr.

Particulars	Qtr Ending Sept. 23	Qtr Ending Sept. 22	Var. (%)
Total Income	4846.90	4251.10	14
OPM (%)	12.95	12.99	- 4 bps
OP	627.50	552.20	14
Other income	26.20	22.60	16
PBIDT	653.70	574.80	14
Net Finance Charges	111.30	92.70	20
PBDT	542.40	482.10	13
Depreciation	163.40	155.00	5
PBT before EO	379.00	327.10	16
EO	1.24	0.00	
PBT after EO	377.76	327.10	15
Tax expense	130.20	114.30	14
PAT	247.56	212.80	16
Minority Interest	15.90	8.80	81
Profit after Minority Interest and Share of profit of Associates	232.90	204.00	14
EPS (Rs)	16.11	14.19	

Apollo Hospitals Q2 results: Net profit up 14% at Rs 233 crore, misses estimate

Chennai-based Apollo Hospitals Enterprise's profit grew 14 per cent y-o-y to Rs.233 crore in Q2 FY24, compared with Rs.204 crore during the corresponding quarter of the previous year.

The hospital operator's overall revenue grew significantly at Rs.4,847 crore (Rs.4,251 crore).

Operating profit margin stood at 12.95% from 12.99%, leading to 14% rise in operating profit to Rs 627.50 crore. Other income rose 16% to Rs 26.20 crore.

Its PBIDT has increased 14 per cent to Rs. 653.70 crore (Rs. 574.80 crore). The company also announced that its digital health platform, Apollo HealthCo, was on track to achieve cash break-even in the fourth quarter of FY24. The platform has seen a significant increase in its user base, revenue and margins in the past six months.

Q2 FY24 Segment-wise

- Healthcare Services (HCS) Revenue at Rs 2,547 crores; 12% YoY growth
- Apollo Diagnostics Revenues crosses landmark of Rs 123 crores in a quarter, Q2 FY24 Revenues at Rs 124 crore for Q2FY24; 19% YoY growth
- Digital Health & Pharmacy Distribution Revenues at Rs 1,945 crores; 1 7% YoY growth GMV of Apollo 247 at Rs 726 crores - 16% QoQ growth;

Expansion plans

- The company announces a 250-bed new hospital in Pune (expandable to 425 beds in 2

Segment Results

In Cr.

	Qtr Ending Sep.23	Qtr Ending Sep.22	VAR %	% to Total
Segment Revenue				
- Healthcare Services	2565.90	2276.60	12.71	53
- Retail Health & Diagnostics	354.20	318.30	11.28	7
- Digital Health & Pharmacy distribution	1945.40	1668.30	16.61	40
- Others	1.20	1.10	9.09	0
Sub - Total	4866.70	4264.30	14.13	100
Less : Interseamental Revenue	19.80	13.10	51.15	
Income from Ooerations	4846.90	4251.20	14.01	
Segment Results				
- Healthcare Services	517.90	458.30	13.00	112
- Retail Health & Diagnostics	2.90	13.20	-78.03	1
- Digital Health & Pharmacy distribution	-51.20	-54.30	-5.71	-11
- Others	-5.60	-6.90	-18.84	-1
Sub - Total	464.00	410.30	13.09	100
Less : Finance Cos	111.30	92.70	20.06	
Add : Other un-allocable income, (net of expenditure)	22.20	22.60	-1.77	
Add : Exceptional item	1.90	0.00		
Add : Share of orofit/(loss) of associates I tolnt ventures	2.20	-13.10	-116.79	
Profit Before Tax	379.00	327.10	15.87	

years) at an overall cost of Rs 675 crs. Hospital is expected to be commissioned by Q1 FY25.

- Expanded footprint in Eastern India with an acquisition of 225 bed hospital in Kolkata; expandable to 325 beds.
- On track to add 2300 beds across 8 locations at a cost of Rs 3,400 crs over the next 3 financial years.

E-mail: researchfeedback@smcindiaonline.com



Corporate Office:
11/6B, Shanti Chamber,
Pusa Road, New Delhi - 110005
Tel: +91-11-30111000
www.smcindiaonline.com

Mumbai Office:
Lotus Corporate Park, A Wing 401/402,
4th Floor, Graham Firth Steel Compound,
Off Western Express Highway, Jay Coach Signal,
Goreagon (East) Mumbai - 400063
Tel: 91-22-67341600, Fax: 91-22-28805606

Kolkata Office:
18, Rabindra Sarani,
Poddar Court, Gate No.- 4, 5th Floor, Kolkata-700001
Tel: 91-33-39847000, Fax: 91-33-39847004

Investments in securities market are subject to market risks, read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. The securities quoted are for illustration only and are not recommendatory. SMC is a SEBI registered Research Analyst having registration number INH100001849. CIN : L74899DL1994PLC063609.

SMC Global Securities Ltd. (hereinafter referred to as "SMC") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. SMC is a registered member of National Stock Exchange of India Limited, Bombay Stock Exchange Limited, MSEI (Metropolitan Stock Exchange of India Ltd) and M/s SMC Comtrade Ltd is a registered member of National Commodity and Derivative Exchange Limited and Multi Commodity Exchanges of India and other commodity exchanges in India. SMC is also registered as a Depository Participant with CDSL and NSDL. SMC's other associates are registered as Merchant Bankers, Portfolio Managers, NBFC with SEBI and Reserve Bank of India. It also has registration with AMFI as a Mutual Fund Distributor.

SMC is a SEBI registered Research Analyst having registration number INH100001849. SMC or its associates has not been debarred/ suspended by SEBI or any other regulatory authority for accessing /dealing in securities market. SMC or its associates or its Research Analyst or his relatives do not hold any financial interest in the subject company interest at the time of publication of this Report. SMC or its associates or its Research Analyst or his relatives do not hold any actual/beneficial ownership of more than 1% (one percent) in the subject company, at the end of the month immediately preceding the date of publication of this Report. SMC or its associates its Research Analyst or his relatives does not have any material conflict of interest at the time of publication of this Report.

SMC or its associates/analyst has not received any compensation from the subject company covered by the Research Analyst during the past twelve months. The subject company has not been a client of SMC during the past twelve months. SMC or its associates has not received any compensation or other benefits from the subject company covered by analyst or third party in connection with the present Research Report. The Research Analyst has not served as an officer, director or employee of the subject company covered by him/her and SMC has not been engaged in the market making activity for the subject company covered by the Research Analyst in this report.

The views expressed by the Research Analyst in this Report are based solely on information available publicly available/internal data/ other reliable sources believed to be true. SMC does not represent/ provide any warranty expressly or impliedly to the accuracy, contents or views expressed herein and investors are advised to independently evaluate the market conditions/risks involved before making any investment decision. The research analysts who have prepared this Report hereby certify that the views /opinions expressed in this Report are their personal independent views/opinions in respect of the subject company.

Disclaimer: This Research Report is for the personal information of the authorized recipient and doesn't construe to be any investment, legal or taxation advice to the investor. It is only for private circulation and use. The Research Report is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon as such. No action is solicited on the basis of the contents of this Research Report. The Research Report should not be reproduced or redistributed to any other person(s) in any form without prior written permission of the SMC. The contents of this material are general and are neither comprehensive nor inclusive. Neither SMC nor any of its affiliates, associates, representatives, directors or employees shall be responsible for any loss or damage that may arise to any person due to any action taken on the basis of this Research Report. It does not constitute personal recommendations or take into account the particular investment objectives, financial situations or needs of an individual client or a corporate/s or any entity/s. All investments involve risk and past performance doesn't guarantee future results. The value of, and income from investments may vary because of the changes in the macro and micro factors given at a certain period of time. The person should use his/her own judgment while taking investment decisions. Please note that SMC its affiliates, Research Analyst, officers, directors, and employees, including persons involved in the preparation or issuance of this Research Report: (a) from time to time, may have long or short positions in, and buy or sell the securities thereof, of the subject company(ies) mentioned here in; or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company(ies) discussed herein or may perform or seek to perform investment banking services for such company(ies) or act as advisor or lender/borrower to such subject company(ies); or (c) may have any other potential conflict of interest with respect to any recommendation and related information and opinions. All disputes shall be subject to the exclusive jurisdiction of Delhi High court.